Literature DB >> 15905995

Early treatment with activated protein C for meningococcal septic shock: case report and literature review.

Tal Hasin, David Leibowitz, David Rot, Yoram Weiss, Tova Chajek-Shaul, Ran Nir-Paz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15905995     DOI： 10.1007/s00134-005-2653-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  14 in total

1.  Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.

Authors:  Esther B Bachli; Stephan R Vavricka; Roland B Walter; Monika I Leschinger; Marco Maggiorini
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

2.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.

Authors:  B White; W Livingstone; C Murphy; A Hodgson; M Rafferty; O P Smith
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 3.  Protein C replacement in severe meningococcemia: rationale and clinical experience.

Authors:  L Alberio; B Lämmle; C T Esmon
Journal:  Clin Infect Dis       Date:  2001-04-09       Impact factor: 9.079

4.  Meningococcal septicaemia: treatment with protein C concentrate.

Authors:  R C Clarke; J R Johnston; E E Mayne
Journal:  Intensive Care Med       Date:  2000-04       Impact factor: 17.440

5.  Human recombinant activated protein C in meningococcal sepsis.

Authors:  Gregory Wcisel; David Joyce; Arna Gudmundsdottir; D Michael Shasby
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

6.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

Authors:  S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

7.  Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome.

Authors:  E Rintala; H Peuravuori; K Pulkki; L M Voipio-Pulkki; T Nevalainen
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

8.  Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans.

Authors:  O P Smith; B White; D Vaughan; M Rafferty; L Claffey; B Lyons; W Casey
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

9.  Treatment of purpura fulminans in meningococcemia with protein C concentrate.

Authors:  G E Rivard; M David; C Farrell; H P Schwarz
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

10.  Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

Authors:  Phil Barton; Andre C Kalil; Simon Nadel; Brahm Goldstein; Regina Okhuysen-Cawley; Richard J Brilli; Jeanne S Takano; Lynn D Martin; Peter Quint; Timothy S Yeh; Heidi J Dalton; Morris R Gessouron; Kellie E Brown; Helen Betts; Michael Levin; William L Macias; David S Small; Virginia L Wyss; Becky M Bates; Barbara G Utterback; Brett P Giroir
Journal:  Pediatrics       Date:  2004-01       Impact factor: 7.124
View more
  2 in total

1.  Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.

Authors:  Gareth L Thomas; Peter Clark
Journal:  Intensive Care Med       Date:  2005-11-10       Impact factor: 17.440

Review 2.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.